Latamoxef Sodium (sterile) Pharma Grade API is a dual-route active pharmaceutical ingredient specified for tablet, capsule, granule, and injectable formulation. The product is supplied as a sterile pharmaceutical-grade sodium salt and is identified for regulatory correspondence by CAS 64953-12-4 and molecular weight 564.44 g/mol; the molecular formula C20H18N6Na2O9S describes the disodium salt of the oxacephem nucleus. Unlike conventional cephalosporin sodium salts, the oxacephem ring replaces sulfur with oxygen at position 1 and carries a 7α-methoxy substituent. This structural arrangement modifies the hydrolytic and β-lactamase degradation pathways that govern both formulation stability and clinical spectrum.

The product model designation covers two release modes: sterile API for injectable presentations and pharma-grade API for oral dosage forms manufactured under non-sterile conditions. The sterile grade is tested against pharmacopoeial sterility and endotoxin requirements; the oral grade follows the same chemical purity and related substances profile but may be released without a sterility claim when the finished product is a tablet, capsule, or granule regulated by non-sterile microbiological criteria. Because the sodium salt is freely water-soluble and hygroscopic, packaging, storage, and dispensing controls are part of the product specification rather than optional handling notes.

How Does the 7α-Methoxy Group Alter β-Lactamase Susceptibility and Differentiate the API?

The replacement of sulfur by oxygen at position 1 shifts the ring system from a cephalosporin to an oxacephem. The 7α-methoxy group introduces steric and electronic effects that reduce recognition by certain serine β-lactamases and extend the compound’s activity against selected Gram-negative anaerobes, particularly Bacteroides fragilis. The 3'-N-methyltetrazole thiol side chain contributes to antimicrobial activity but is also linked to hypoprothrombinemia and disulfiram-like reactions after alcohol exposure. This intrinsic side-effect boundary is not a formulation defect; it differentiates Latamoxef Sodium from ceftriaxone sodium and cefotaxime sodium APIs and requires prescribing information to include vitamin K monitoring when clinically indicated. From a chemical control perspective, the oxacephem nucleus and NMTT side chain require tighter related substances monitoring than first-generation cephalosporin sodium salts because trace hydrolytic products can form in aqueous solution and generate color or particulate matter. HPLC methods using C18 stationary phases, high aqueous mobile phases, and ultraviolet detection are commonly applied; method validation follows ICH Q2(R1) and USP <621>. Published data for the specific degradation products of this API are available in pharmacopoeial monographs and registration dossiers; impurity thresholds are set according to ICH Q3A and Q3B exposure limits.

Residual solvent profiles in multi-step synthesis often include acetone, ethyl acetate, or isopropanol; these are controlled as Class 3 solvents under ICH Q3C. If higher-risk solvents are used in the final crystallization or drying stages, their limits are set to a concentration corresponding to no more than the permitted daily exposure. Residual elemental impurities are tested by compendial procedures such as USP <232>/<233>; the sodium salt is not considered interchangeable with cephalosporin sodium salts that carry a different counterion profile or different residual solvent specifications without comparative release data.

Aseptic Filling Lines, Lyophilization, and Terminal Sterilization Constraints for Injectable Presentations

Injectable presentations of Latamoxef Sodium (sterile) API are filled as dry powder or lyophilized cake in vials. Terminal steam sterilization is generally unsuitable because the β-lactam ring undergoes hydrolysis at elevated temperature. Aseptic processing therefore starts with sterile API and proceeds through sterile filtration of the dissolved drug, sterile transfer, and filling under Grade A unidirectional airflow in an isolator or restricted access barrier system. EU GMP Annex 1 cleanroom limits and ISO 14644-1 classification apply; media fills and container closure integrity testing are part of the injection-line qualification. The filling solution is typically maintained at 2–8 °C to suppress hydrolytic degradation during batch hold time. Before aseptic filling, the API is de-lumped through a sterile sieve with mesh openings in the 0.5 mm to 1.0 mm range; this step reduces agglomerates that would otherwise obstruct dosing nozzles or dissolve slowly during reconstitution. Powder flow for vial filling is characterized by bulk density and conditioned density rather than by single-particle size alone. Vacuum dosator fillers and auger fillers require specification of both loose and tapped density because variations in these values alter fill weight and dose uniformity across the batch.

Lyophilized presentations require a formulation matrix that protects the API during freezing and primary drying. Bulking agents such as mannitol or glycine may be used, but their compatibility with the sodium salt should be confirmed by differential scanning calorimetry and freeze-drying microscopy. Collapse temperature and glass transition temperature of the maximally freeze-concentrated solution determine the primary drying shelf temperature; the API’s high water solubility can lower the collapse temperature of the formulation, requiring conservative ramp rates and chamber pressure. After lyophilization, residual moisture is controlled by Karl Fischer titration to prevent hydrolysis in the sealed vial; vial headspace oxygen is reduced by nitrogen flushing because the oxacephem ring may undergo oxidative degradation. The stopper and seal configuration is selected to resist moisture ingress over shelf life; bromobutyl stoppers are common but require extractable and leachable assessment under USP <1663> and USP <1664>.

For oral tablet and capsule formulation, the same sodium salt is used, but the manufacturing train is generally non-sterile. The API is freely water-soluble and hygroscopic; therefore direct compression blends may exhibit sticking, picking, and variable tablet weight when tablet press tooling is not cooled or when relative humidity in the compression suite exceeds 60% RH. The sodium salt should be dispensed in a low-humidity suite and not held in open containers. Incompatibility with primary amines and strongly nucleophilic excipients should be assessed because β-lactam ring opening can produce inactive derivatives. Aqueous wet granulation is normally avoided unless simultaneous heat and moisture exposure is justified by stability data; dry granulation by roller compaction is preferred.

Granule and dry-syrup presentations require particle size control beyond simple sieve analysis. The API is often geometrically diluted with spray-dried lactose, mannitol, or microcrystalline cellulose in a bin blender of 100–1000 L working volume; blend uniformity is verified with thief sampling and analyzed by HPLC according to USP <905>. If a wet granulation step is unavoidable, non-aqueous binders or limited water addition with rapid drying in a fluid-bed dryer is used. The API should not be exposed to prolonged wet massing because sodium salt hydration and localized low pH can initiate hydrolytic degradation. Drying endpoint is controlled by near-infrared moisture probes calibrated against Karl Fischer; under-drying accelerates hydrolysis, while overdrying can increase static charge and reduce flowability. For capsules, the granulate is filled on automatic tamping or dosator machines that require controlled bulk density and flow function; hopper vibration and feed shoe overfilling are adjusted to prevent particle segregation.

When Tablet, Capsule, or Granule Presentations Require Enteric Coating and Taste Masking

Oral bioavailability of the sodium salt is constrained by ionization and acid-catalyzed degradation in the stomach; therefore an immediate-release oral tablet without enteric protection may show poor and variable absorption. If an enteric coating is applied, the coating level is critical: an incomplete coat exposes the API to gastric acid, while excessive coating delays release beyond the optimal absorption window. Dissolution testing is conducted using USP <711> apparatus 1 or 2, with acid-stage and buffer-stage media selected to demonstrate gastric resistance and intestinal release. Taste masking is also a requirement for pediatric granules and dry syrups. Coating of granules with ethylcellulose, methacrylic acid copolymers, or lipid matrices may be used, but the coating must not contain reactive amine plasticizers that can accelerate β-lactam ring opening. Stability under accelerated conditions at 40 °C/75% RH and long-term conditions at 25 °C/60% RH should include assay, related substances, dissolution, and moisture content; the sodium salt may show visible darkening before assay loss if headspace oxygen is not controlled.

The differentiation of Latamoxef Sodium from other β-lactam APIs is summarized in the comparison matrix below. The comparison is based on molecular properties and typical processing constraints, not on clinical superiority or therapeutic substitution.

Process analytical technology on production lines can link near-infrared moisture measurements, particle size data, and HPLC impurity data to control batch-to-batch variability. In injectable filling, the dissolved API is filtered through sterile hydrophilic PVDF or PES membranes; the membrane manufacturer’s chemical compatibility data should be required because the sodium salt alters ionic strength and may change filter flux. Adsorption losses on nylon filters should be evaluated during filtration validation, and the final filling solution is sampled for bioburden before sterilizing-grade filtration. The constituted solution should be checked for pH, color, clarity, and reconstitution time because visible particulate formation in the presence of residual moisture or incompatible closure coatings is a known failure mode on production lines handling hygroscopic β-lactam sodium salts.